See all job openings posted by The Column Group's portfolio companies on our Careers page! https://lnkd.in/gtyHpGbq
The Column Group
Venture Capital and Private Equity Principals
San Francisco, CA 4,610 followers
Extraordinary starts here... the bold pursuit of big ideas using innovative science to generate breakthrough therapies.
About us
The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics. TCG’s investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product-orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma “buyer” as key investment considerations. In contrast, TCG takes the long view in making investments, recognizing that significant time is often required to generate significant value. Our approach is not “building-to-exit.” Key variables, including scientific opportunities, the competitive and regulatory landscape, and Pharma priorities, can change very rapidly. Instead, TCG’s mission is the generation of fundamentally strong companies, built from the ground up based on great science and the ability to generate multiple differentiated product opportunities. Rather than diversification, TCG emphasizes focus. We are dedicated to early stage drug discovery as the best source of a new generation of novel, highly effective human therapies. We believe that the most critical resources, such as great ideas, world class founders, and top quality managerial and scientific talent, are very rare and that concentrating them within a small cohort of companies is the key path to success. TCG is about the bold pursuit of big ideas using innovative science to generate breakthrough therapies that address significant diseases. Our firm is committed to all facets of company building and brings together a rich combination of scientific, financial and operational expertise to shape promising science into a value-rich portfolio poised to have a profound impact on human health.
- Website
-
http://www.thecolumngroup.com
External link for The Column Group
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
San Francisco, CA, US
Employees at The Column Group
Updates
-
NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum https://lnkd.in/gqkJAJyF
NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum | NGM Biopharmaceuticals, Inc.
news.ngmbio.com
-
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer https://lnkd.in/geXmr85B
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer | ORIC Pharmaceuticals, Inc.
investors.oricpharma.com
-
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update https://lnkd.in/e4fmcsBR
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | Nurix Therapeutics, Inc.
ir.nurixtx.com
-
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration https://lnkd.in/gqXTMcqH
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration - Remix Therapeutics
https://www.remixtx.com
-
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy https://lnkd.in/gdeiZKij
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy
globenewswire.com
-
Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors https://lnkd.in/gwNuyt2c
Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors
https://circlepharma.com
-
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy https://lnkd.in/eJHzyZ6P
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy
neuronatherapeutics.com
-
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-8638 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) https://lnkd.in/gEs5H_NW
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-8638 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) | Nurix Therapeutics, Inc.
ir.nurixtx.com
-
InduPro Announces $85 Million Series A Financing, Appoints Prakash Raman, Ph.D. as CEO to Advance Next-Generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Diseases https://lnkd.in/e4dmG_b3
InduPro Announces $85 Million Series A Financing, Appoints Prakash Raman, Ph.D. as CEO to Advance Next-Generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Diseases
prnewswire.com